$IMA News
Last published 2d ago
- 2d agoIMAImageneBio, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2d agoIMAImageneBio Reports Third Quarter 2026 Financial ResultsGlobeNewswireSAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA) ("Imagene" or the "Company") today reported financial results for the quarter ended September 30, 2026, and provided a company
- 2mo agoIMAImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New YorkGlobeNewswireSAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA) ("Imagene" or the "Company") today announced that chief executive officer Kristin Yarema, Ph.D., will participate in a
- 2mo agoIMAImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA) ("Imagene" or the "Company") today announced that on August 14, 2026, the Compensation Committee of the Company’s Board of
- 3mo agoIMAImageneBio Reports Second Quarter 2026 Financial ResultsGlobeNewswireSAN DIEGO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA) ("Imagene" or the "Company") today reported financial results for the quarter ended June 30, 2026, and provided a company
- 4mo agoIMAImageneBio Appoints Matt Robbins as General CounselGlobeNewswireSAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene" or the "Company")), today announced the appointment of Matt Robbins, an experienced life sciences attorney with more
- 5mo agoIMAImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New YorkGlobeNewswireSAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA) ("Imagene" or the "Company") today announced that chief executive officer Kristin Yarema, Ph.D., will present at the Jefferies Global Healthcare
- 6mo agoIMAImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program UpdateGlobeNewswireSAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA) ("Imagene" or the "Company") today reported financial results for the quarter ended March 31, 2026, and provided an update for
- 7mo agoIMAImageneBio Announces $30 Million Private PlacementGlobeNewswirePrivate placement led by Coastlands Capital with participation from additional new and existing investors Proceeds will support further development of IMG-007 in alopecia areata and late-stage development activities for
- 8mo agoIMAImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company UpdateGlobeNewswireSAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA) ("Imagene" or the "Company") today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a
- 8mo agoIMAImageneBio to Participate in Leerink Global Healthcare ConferenceGlobeNewswireSAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " or the "Company")), today announced management will participate in a fireside chat and hold one-on-one meetings at the 2026 Leerink
- 9mo agoIMAMLTXImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical OfficerGlobeNewswireBrings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion of the Phase
- 12mo agoIMAImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management TeamGlobeNewswire$142.6 million cash and cash equivalents and marketable securities as of September 30, 2025 Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis (AD) announced to optimize study design
- 1y agoIMAImageneBio to Participate in Fourth Quarter 2025 Investor ConferencesGlobeNewswireSAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " "Company")), a clinical-stage biotechnology company developing therapeutics for patients with immunological, autoimmune and
- 1y agoIMAImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA) ("ImageneBio"), a clinical stage biotechnology company dedicated to developing treatments for immunological/autoimmune and inflammatory
- 5y agoIMAIMAX Corp. to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / April 29, 2021 / IMAX Corp. (NYSE:IMA) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on April 29, 2021 at 8:30 AM Eastern Time. To listen to the event live or access a replay o